• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Janssen Launches Plaque Psoriasis Trial Aimed at Racial and Ethnic Minorities

Janssen Launches Plaque Psoriasis Trial Aimed at Racial and Ethnic Minorities

March 28, 2022

Janssen has initiated a first-of-its-kind, large-scale trial of its plaque psoriasis monoclonal antibody Tremfya (guselkumab) that will only enroll minority participants.

The phase 3b multicenter trial will assess the safety and efficacy of Tremfya in patients who identify as non-White and aims to enroll around 200 U.S. and Canadian patients with moderate-to-severe plaque psoriasis and/or moderate-to-severe scalp psoriasis. Participants will be monitored for approximately two years.

The trial will deliver additional data and information on psoriatic disease burden and the patient journey in Black, Hispanic, Asian and Native American patients, and other minorities. Although Tremfya’s safety and efficacy profile is well-established across an extensive adult population, there’s still a need for further information on its safety and efficacy in minorities. According to Janssen, the majority of phase 3 psoriasis trials across topical, oral and biologic drugs (86 percent) have enrolled mostly White patients.

 

To view more CenterWatch Weekly stories, click here.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing